Drugs Made In America Acquisition Corp. - Ordinary Shares, $0.0001 par value (DMAA)

33 filings reported holding DMAA - Drugs Made In America Acquisition Corp. - Ordinary Shares, $0.0001 par value as of Q2 2025.
Drugs Made In America Acquisition Corp. - Ordinary Shares, $0.0001 par value (DMAA) has 32 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 20.8M shares of 33.5M outstanding shares and own 62.07% of the company stock.
Largest 10 shareholders include Karpus Management, Inc. (2.74M shares), First Trust Capital Management L.P. (2.24M shares), Polar Asset Management Partners Inc. (1.9M shares), GLAZER CAPITAL, LLC (1.82M shares), Hudson Bay Capital Management LP (1.8M shares), Westchester Capital Management, LLC (1.67M shares), WOLVERINE ASSET MANAGEMENT LLC (1.02M shares), MIZUHO SECURITIES USA LLC (920K shares), ARISTEIA CAPITAL, L.L.C. (882K shares), and D. E. Shaw & Co., Inc. (690K shares).
This table shows the top 32 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.